Opicapone

• Description :

  Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC50 of 98 μM[1].

• Product Name Alternative :

  BIA 9-1067

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  COMT

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/opicapone.html

• Purity :

  99.19

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  CC1=[N+]([O-])C(Cl)=C(C2=NOC(C3=CC([N+]([O-])=O)=C(O)C(O)=C3)=N2)C(C)=C1Cl

• Molecular Formula :

  C15H10Cl2N4O6

• Molecular Weight :

  413.17

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Bonifácio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172 (7) :1739-52.|[2]Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15 (2) :154-165.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [923287-50-7]